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a b s t r a c t
Transfusion of blood and blood products contaminated with the pathogenic form of prion protein Prpsc,
thought to be the causative agent of variant a Creutzfeldt–Jakob disease (vCJD), may result in serious
consequences in recipients with a compromised immune system, for example, as seen in HIV-1 infection.
In the present study, we demonstrate that treatment of peripheral blood monocyte-derived macro-
phages (MDM) with PrP106–126, a synthetic domain of PrP
sc that has intrinsic functional activities related
to the full-length protein, markedly increased their susceptibility to HIV-1 infection, induced cytokine
secretion, and enhanced their migratory behavior in response to N-formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLP). Live-cell imaging of MDM cultured in the presence of PrP106–126 showed large
cell clusters indicative of cellular activation. Tyrosine kinase inhibitor STI-571, protein kinase C inhibitor
K252B, and cyclin-dependent kinase inhibitor olomoucine attenuated PrP106–126-induced altered MDM
functions. These ﬁndings delineate a previously undeﬁned functional role of PrP106–126-mediated host
cell response in promoting HIV-1 pathogenesis.
Published by Elsevier Inc.
Introduction
Transmissible spongiform encephalopathies (TSEs) are fatal neu-
rodegenerative disorders in both animals and humans (Beisel and
Morens, 2004). In most TSE-affected individuals, abnormal prion
protein (PrPsc) accumulates in the brain, where it is thought to play
both direct and indirect roles in the pathogenesis of prion diseases.
PrP is also found in a wide variety of peripheral tissues, including
mononuclear blood cells (Cashman et al., 1990). With the identiﬁca-
tion of the variant vCJD, there were concerns that PrPsc might be
inadvertently transmissible via iatrogenic routes, including use of
blood and blood products (Sutton et al., 2006; McDonnell and
Burke, 2003; Peden et al., 2005; O'Dowd, 2013); these concerns have
since been borne out. Thus, individuals with a compromised immune
system, especially HIV-1-infected patients, may be at a higher risk for
disease complications.
In the present study, we have used the synthetic peptide PrP106–126
as a model to evaluate the relationship between HIV-1 and PrPsc and
to deﬁne a possible role of PrPsc in the pathogenesis of HIV-1 infection.
We have shown that exposure of human MDM to the PrP106–126
activated MDM, enhanced their susceptibility to HIV-1 infection, and
promoted their migratory activity. Since the transmission of TSE
infectivity, if present in blood or blood products testing negative for
HIV and other pathogens, could constitute a serious health hazard for
the recipients, our studies may provide useful insights into the
pathogenesis of TSE-HIV-1 co-infection.
Results and discussion
Transfusion of tainted blood or blood products has been demon-
strated to be a mode of transmission of the vCJD to recipients
(Llewelyn et al., 2004). Pathogenic consequences of TSE transmission
to HIV-1-infected patients whose immune system is already severely
compromised may be detrimental to the recipients disease status.
Although there are no reports yet documenting increased incidence of
the vCJD in general HIV-infected patients, addressing this previously
undeﬁned subject will advance our understanding of HIV-1 patho-
genesis in TSE-HIV-1 co-infection.
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Treatment of MDM with PrP106–126 increased their susceptibility to
HIV-1 infection in a dose-dependent manner (Fig. 1A). PrP106–126
promoted HIV replication in MDM when treated 24 h before, at the
time of, or even 2 h after infection (Fig. 1B). Consistent with the
enhancement of viral replication, PrP106–126 treatment produced a
marked increase in HIV-associated cytopathic effects in MDM as
evident by the formation of multinucleated giant cells (Fig. 1C).
Live-cell imaging of MDM cultured in the presence of PrP106–126
for 72 h revealed marked aggregation of cells in discrete clusters,
while similar incubations of untreated MDM or those treated with
control ScrPrP peptide did not promote the formation of multi-
cellular aggregates (Fig. 1D). Such homotypic aggregation of cells
eventually resulted in the formation of increased numbers of
multinucleated giant cells after HIV-1 infection (as shown in
Fig. 1C). These data suggest that treatment of MDM with PrP106–126
may be sufﬁcient to initiate cell aggregation, but productive HIV
infection is required for syncytium formation. Thus, our results
provide strong support for recognizing a critical role of PrP-
induced cellular activation in promoting HIV infection.
The cellular and molecular neuropathology of TSE, Parkinson's
disease, and Alzheimer's disease suggest proinﬂammatory cytokines
as possible pathogenic mediators in neurodegenerative disease (Bacot
et al., 2003; McGeer et al., 1993; Kim et al., 1999; Williams et al., 1994,
1997). We examined for PrP106–126 induction of cytokine secretion by
MDM. Consistent with previous reports (Lu et al., 2012; Fabrizi et al.,
2001), we found signiﬁcantly elevated levels of IL-1β, IL-6 and TNFα in
Fig. 1. PrP106–126 activation promotes HIV-1 infection of primary human MDM. Panel A. MDM treated with various concentrations of PrP106–126 24 h prior to inoculation with
HIV-1. Culture ﬂuid was harvested 7 days after infection and assayed for HIV-1-p24. Panel B. HIV-1 p24 levels measured on day 7 in the culture supernatants from HIV-
infected MDM treated with PrP106–126 (25 μM) 24 h before, at the time of, and 2 h after infection. Panel C. HIV-induced cytopathic effects in monocytes infected with HIV in
the absence or the presence of 25 μM PrP. Panel D. PrP106–126-induced activation of primary human MDM by live-cell imaging for the formation of cell aggregates
(arrowheads).
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the culture supernatants of MDM cultured for 24 h in the presence of
PrP106–126. These cytokines were nearly undetectable in culture super-
natants from the untreated MDM or those treated with the control
ScrPrP peptide (Fig. 2).
Macrophages are widely circulating cells of the immune system
with the ability to migrate across the endothelium (Westhorpe et al.,
2009; Rezaie and Al-Sarraj, 2007). They are known targets for HIV-1
infection, and are thought to be involved in the transmission of TSE
infection. To examine the ability of PrP106–126 to promote the
migratory activity of macrophages, we performed chemotactic assays
on uninfected and HIV-1-infected MDM cultured in the absence or
presence of PrP106–126, using fMLP as a chemoattractant. Treatment of
the monocytes with 25 μM PrP106–126 for 24 h signiﬁcantly increased
their migratory response to fMLP. This increase in migratory behavior
persisted in MDM in which PrP106–126 activation promoted the
migration of both uninfected and HIV-1-infected MDM (Fig. 3A) in
response to fMLP. PrP106–126 has been reported to induce themigration
of macrophages (Zhou et al., 2009). Our results conﬁrm these ﬁndings
and demonstrate that PrP106–126 have a potent chemotactic effect on
MDM (Fig. 3B). To evaluate PrP106–126 peptide speciﬁcity in activating
MDM, we used the chemokine polypeptide LD78b as an additional
control. As shown in Fig. 3, even though LD78β induced the migration
of MDM similar to PrP106–126 when used as a chemoattractant, it
suppressed HIV replication in infected cells (Fig. 3C). Taken together,
these ﬁndings indicate that PrPsc may play an important role in
modulating some of the immunological functions ascribed to speciﬁc
cells in immune disorders.
The mechanism by which our peptide fragment induces MDM
activation and causes altered biological functions might be due to
PrP106–126-mediated signal transduction. To test this hypothesis,
MDM were incubated with PrP106–126 in the presence of various
concentrations of tyrosine kinase inhibitor STI-571, protein kinase C
inhibitor K252B, and cyclin-dependent kinase inhibitor olomoucine,
and then infected with HIV-1. Cell-free virus was quantiﬁed by an HIV-
1-p24 ELISA on day 7, and cell migration was evaluated by chemotaxis
assay. As shown in Fig. 4, all inhibitors substantially attenuated HIV-1
replication, even in cells not treated with PrP106–126; however, the
PrP106–126-induced increase in HIV-1 replication was markedly sup-
pressed (Panels A–C). Similarly, these inhibitors inhibited the migra-
tion of both untreated and PrP106–126-treated MDM in response to
fMLP; however, migratory activity of PrP-activated MDM in response
to fMLP was much lower (Panels D–F). Although the downstream
pathways through which PrP106–126 stimulates various kinases in
MDM remain to be elucidated, our studies using PrP106–126 as a model
for PrPSc can provide a basis for understanding the functional role of
PrPsc in cellular activation resulting in the progression of HIV-1
infection. PrP106–126 activation of MDM is consistent with our previous
observations of PrP-induced stimulation of proinﬂammatory responses
in human monocyte-derived dendritic cells (Bacot et al., 2003).
Because of the current absence of a sensitive diagnostic assay, PrPsc
(and by extension, TSE infectivity) is not yet detectable in blood, and
concerns remain about transmission of this pathogenic agent through
blood transfusion (O'Dowd, 2013; Farrugia, 2002; Hunter et al., 2002;
Gregori et al., 2011; Houston et al., 2008). In summary, the ﬁndings of
the present study provide strong evidence for a role of PrPsc in
promoting the pathogenesis of HIV-1 infection.
Fig. 2. PrP106-126 activation promotes inﬂammatory cytokine production by pri-
mary human MDM. Panel A: IL-1β; panel B: IL-6; panel c: TNFα.
Fig. 3. Panel A. PrP106–126-induced chemotactic activity of uninfected and HIV-1-
infected MDM in response to fMLP. Panel B. Chemotactic response of MDM in
response to PrP106–126. The number of migrated cells attached to the underside of
the ﬁlter was determined by high power microscope ﬁeld (hpf) in triplicate for each
well, and experiments were conducted in groups of three for each experimental
point as described in the section “Methods”. Panel C. Effect of PrP106–126 and LD78b
on HIV replication in MDM. MDM were cultured in the absence or presence of
25 μM PrP106–126 or 100 ng/ml LD78β for 7 days at 37 1C. Culture ﬂuid was
harvested 7 days after infection and assayed for HIV-1-p24. Error bars indicate
standard deviations poo0.05.
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Methods
Human MDMs were generated from normal donors (Wahl et al.,
1984) infected with HIV-1BaL as described, (Devadas and Dhawan,
2006) andmaintained in DMEM supplemented with 10% FBS, 20 μg/ml
gentamicin, and 1000 U/ml macrophage colony stimulation factor (M-
CSF). Culture media was replenished with fresh media every other day.
HIV replication was quantiﬁed by measuring cell-free HIV-p24 in
culture supernatants using the NEN/Dupont ELISA analysis kit (Perkin
Elmer Life Sciences, Inc., Boston, MA) according to the manufacturer's
instructions as previously described (Devadas and Dhawan, 2006).
A synthetic peptide corresponding to amino acid residues 106–126
of the PrPsc (PrP106–126), known to contain biological activity, (Forloni
et al., 1993; Selvaggini et al., 1993) was synthesized in-house as
described previously (Bacot et al., 2003). Biological activity of the
PrP106–126 peptide was tested by calcium mobilization analysis (Bacot
et al., 2003). A scrambled prion peptide (ScrPrP), purchased from
Sigma-Aldrich, St. Louis, MO, was used as a negative control. In-house
peptides were extracted three times using a solution of 50:50
acetonitrile (Baxter, Muskegon, MI):H2O (v/v) and dissolved in water
at a concentration of 1 mM.
MDM were cultured in the absence or presence of ScrPrP106–126
(control prion peptide), or PrP106–126 (functional prion peptide) at
37 1C for up to 72 h. Cell culture morphology was monitored with
parallel inverted microscopes equipped for phase-contrast microscopy
(Zeiss Axiovert 25) with 37 1C humidiﬁed chambers at 10% CO2
(Precision Plastics) using 5X Zeiss A Plan, 0.12N.A. objectives. Images
were collected with digital cameras (Inﬁnity2; Luminera) at 10 min
intervals using Inﬁnity2 software, and the contrast and brightness of
images were adjusted in parallel using Photoshop software.
Supernatants of media collected fromMDM cultured for 24 h at
37 1C in the absence or presence of PrP106–126 or ScrPrP were
analyzed for IL-1β, IL-6, and TNFα. Cytokine levels were deter-
mined by using the ELISA kits from R&D Systems according to the
manufacturer's instructions.
Cell migration assays were conducted in 48-well microchemotaxis
chambers (Neuroprobe Inc., Gaithersburg, MD) (Zhou et al., 2009).
Brieﬂy, untreated and PrP106–126-treated MDM were placed in the
upper chambers. FMLP, used as a chemoattractant at a concentration
of 108 M in a volume of 26 μl of RPMI containing 1 mg/ml BSA, was
placed in the lower chambers. A polycarbonate polyvinylpyrrolidone-
free ﬁlter with a pore size of 8 mm (Neuroprobe) was then placed over
the lower chambers, and the unit was assembled. The chambers were
incubated for 3 h at 37 1C. The ﬁlters were then carefully removed,
ﬁxed, and stained with Diff-Quick stain (Fisher Scientiﬁc). Cells on the
upper side of the ﬁlter were removed, and those attached to the
underside of the ﬁlter were counted using a high power microscope
ﬁeld (1.4 mm2) in triplicats for each well.
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Fig. 4. Inhibition of PrP106–126-induced HIV-1 replication in MDM by protein kinase inhibitors. Panels A–C. MDM were pre-treated with the indicated protein kinase
inhibitors (0–1 μM) 30 min prior to HIV-1 infection. Culture ﬂuids were harvested 7 days after infection, and cell-free HIV-1-p24 was determined by ELISA. Panels D–F.
Inhibition of PrP106–126-induced migration of MDMs by protein kinase inhibitors. MDMs were pre-treated for 30 min with the indicated protein kinase inhibitors (0–1 μM)
and then incubated in the presence of 25 μM PrP106–126 for 24 h at 37 1C before being assessed for chemotactic potential as described in the section “Methods”. The number of
cells attached to the underside of the ﬁlter was determined in triplicate for each well, and experiments were conducted in groups of three for each experimental point. Error
bars indicate standard deviations. poo0.05.
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